Home > Publications Database > The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation. > print

001     274040
005     20260212171140.0
024 7 _ |2 doi
|a 10.3389/fnins.2024.1502246
024 7 _ |2 pmid
|a pmid:39726830
024 7 _ |2 pmc
|a pmc:PMC11669673
024 7 _ |2 ISSN
|a 1662-4548
024 7 _ |2 ISSN
|a 1662-453X
024 7 _ |2 altmetric
|a altmetric:172562134
037 _ _ |a DZNE-2025-00021
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Knab, Felix
|b 0
245 _ _ |a The cellular and extracellular proteomic signature of human dopaminergic neurons carrying the LRRK2 G2019S mutation.
260 _ _ |a Lausanne
|b Frontiers Research Foundation
|c 2024
336 7 _ |2 DRIVER
|a article
336 7 _ |2 DataCite
|a Output Types/Journal article
336 7 _ |0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
|a Journal Article
|b journal
|m journal
|s 1736338671_683
336 7 _ |2 BibTeX
|a ARTICLE
336 7 _ |2 ORCID
|a JOURNAL_ARTICLE
336 7 _ |0 0
|2 EndNote
|a Journal Article
520 _ _ |a Extracellular vesicles are easily accessible in various biofluids and allow the assessment of disease-related changes in the proteome. This has made them a promising target for biomarker studies, especially in the field of neurodegeneration where access to diseased tissue is very limited. Genetic variants in the LRRK2 gene have been linked to both familial and sporadic forms of Parkinson's disease. With LRRK2 inhibitors entering clinical trials, there is an unmet need for biomarkers that reflect LRRK2-specific pathology and target engagement.In this study, we used induced pluripotent stem cells derived from a patient with Parkinson's disease carrying the LRRK2 G2019S mutation and an isogenic gene-corrected control to generate human dopaminergic neurons. We isolated extracellular vesicles and neuronal cell lysates and characterized their proteomic signature using data-independent acquisition proteomics. Then, we performed differential expression analysis to identify dysregulated proteins in the mutated line. We used Metascape and gene ontology enrichment analysis on the dysregulated proteomes to identify changes in associated functional networks.We identified 595 significantly differentially regulated proteins in extracellular vesicles and 3,205 in cell lysates. We visualized functionally relevant protein-protein interaction networks and identified key regulators within the dysregulated proteomes. Using gene ontology, we found a close association with biological processes relevant to neurodegeneration and Parkinson's disease. Finally, we focused on proteins that were dysregulated in both the extracellular and cellular proteomes. We provide a list of ten biomarker candidates that are functionally relevant to neurodegeneration and linked to LRRK2-associated pathology, for example, the sonic hedgehog signaling molecule, a protein that has tightly been linked to LRRK2-related disruption of cilia function.In conclusion, we characterized the cellular and extracellular proteome of dopaminergic neurons carrying the LRRK2 G2019S mutation and proposed an experimentally based list of biomarker candidates for future studies.
536 _ _ |0 G:(DE-HGF)POF4-352
|a 352 - Disease Mechanisms (POF4-352)
|c POF4-352
|f POF IV
|x 0
536 _ _ |0 G:(DE-HGF)POF4-353
|a 353 - Clinical and Health Care Research (POF4-353)
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |2 Other
|a LRRK2
650 _ 7 |2 Other
|a Parkinson’s disease
650 _ 7 |2 Other
|a biomarker
650 _ 7 |2 Other
|a extracellular vesicle
650 _ 7 |2 Other
|a induced pluripotent stem cell
700 1 _ |0 P:(DE-2719)2811633
|a Guaitoli, Giambattista
|b 1
|u dzne
700 1 _ |a Jarboui, Mohamed Ali
|b 2
700 1 _ |0 P:(DE-2719)2811552
|a von Zweydorf, Felix
|b 3
|u dzne
700 1 _ |a Isik, Fatma Busra
|b 4
700 1 _ |a Klose, Franziska
|b 5
700 1 _ |a Rajkumar, Anto Praveen
|b 6
700 1 _ |0 P:(DE-2719)2320009
|a Gasser, Thomas
|b 7
|u dzne
700 1 _ |0 P:(DE-2719)2811291
|a Gloeckner, Christian Johannes
|b 8
|e Last author
|u dzne
773 _ _ |0 PERI:(DE-600)2411902-7
|a 10.3389/fnins.2024.1502246
|g Vol. 18, p. 1502246
|p 1502246
|t Frontiers in neuroscience
|v 18
|x 1662-4548
|y 2024
856 4 _ |u https://pub.dzne.de/record/274040/files/DZNE-2025-00021.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/274040/files/DZNE-2025-00021.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:274040
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2811633
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 1
|k DZNE
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2811552
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 3
|k DZNE
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2320009
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 7
|k DZNE
910 1 _ |0 I:(DE-588)1065079516
|6 P:(DE-2719)2811291
|a Deutsches Zentrum für Neurodegenerative Erkrankungen
|b 8
|k DZNE
913 1 _ |0 G:(DE-HGF)POF4-352
|1 G:(DE-HGF)POF4-350
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|v Disease Mechanisms
|x 0
913 1 _ |0 G:(DE-HGF)POF4-353
|1 G:(DE-HGF)POF4-350
|2 G:(DE-HGF)POF4-300
|3 G:(DE-HGF)POF4
|4 G:(DE-HGF)POF
|a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2024
915 _ _ |0 StatID:(DE-HGF)0200
|2 StatID
|a DBCoverage
|b SCOPUS
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0160
|2 StatID
|a DBCoverage
|b Essential Science Indicators
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1050
|2 StatID
|a DBCoverage
|b BIOSIS Previews
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1190
|2 StatID
|a DBCoverage
|b Biological Abstracts
|d 2023-08-26
915 _ _ |0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
|a Creative Commons Attribution CC BY 4.0
915 _ _ |0 StatID:(DE-HGF)0100
|2 StatID
|a JCR
|b FRONT NEUROSCI-SWITZ : 2022
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0501
|2 StatID
|a DBCoverage
|b DOAJ Seal
|d 2021-05-11T13:19:45Z
915 _ _ |0 StatID:(DE-HGF)0500
|2 StatID
|a DBCoverage
|b DOAJ
|d 2021-05-11T13:19:45Z
915 _ _ |0 StatID:(DE-HGF)0113
|2 StatID
|a WoS
|b Science Citation Index Expanded
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0700
|2 StatID
|a Fees
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0150
|2 StatID
|a DBCoverage
|b Web of Science Core Collection
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)1110
|2 StatID
|a DBCoverage
|b Current Contents - Clinical Medicine
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0510
|2 StatID
|a OpenAccess
915 _ _ |0 StatID:(DE-HGF)0030
|2 StatID
|a Peer Review
|b DOAJ : Anonymous peer review
|d 2021-05-11T13:19:45Z
915 _ _ |0 StatID:(DE-HGF)0561
|2 StatID
|a Article Processing Charges
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)9900
|2 StatID
|a IF < 5
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0300
|2 StatID
|a DBCoverage
|b Medline
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0320
|2 StatID
|a DBCoverage
|b PubMed Central
|d 2023-08-26
915 _ _ |0 StatID:(DE-HGF)0199
|2 StatID
|a DBCoverage
|b Clarivate Analytics Master Journal List
|d 2023-08-26
920 1 _ |0 I:(DE-2719)1210007
|k AG Gloeckner
|l Functional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases
|x 0
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210007
980 _ _ |a I:(DE-2719)1210000
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21